Beta2 (ß2)-agonist medications ... Both short-acting ß2-agonists (SABAs) and long-acting ß2-agonists (LABAs) play ...

b p represents the level of significance for the comparison between patients who filled an initial prescription for a long-acting β 2-adrenergic agonist before FDA alerts versus after the FDA alerts.

A respiratory diagnosis of asthma only was found in 39.3% of all patients, COPD only in 4.7% of patients, and asthma plus COPD in 3.0% of patients. Approximately 53% of patients did not have a ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA ... as a once-daily maintenance treatment for patients whose asthma can’t be controlled with two-drug LABA/ICS drugs ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...